EP1898973B2 - Apparatus for testing a filter - Google Patents

Apparatus for testing a filter Download PDF

Info

Publication number
EP1898973B2
EP1898973B2 EP05762877.8A EP05762877A EP1898973B2 EP 1898973 B2 EP1898973 B2 EP 1898973B2 EP 05762877 A EP05762877 A EP 05762877A EP 1898973 B2 EP1898973 B2 EP 1898973B2
Authority
EP
European Patent Office
Prior art keywords
chamber
pressure
filter
pump
line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05762877.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1898973A1 (en
EP1898973B1 (en
Inventor
Renato Pedrazzi
Mauro Suffritti
Anna Puppini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gambro Lundia AB
Original Assignee
Gambro Lundia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36353310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1898973(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gambro Lundia AB filed Critical Gambro Lundia AB
Priority to PL05762877T priority Critical patent/PL1898973T5/pl
Publication of EP1898973A1 publication Critical patent/EP1898973A1/en
Publication of EP1898973B1 publication Critical patent/EP1898973B1/en
Application granted granted Critical
Publication of EP1898973B2 publication Critical patent/EP1898973B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1621—Constructional aspects thereof
    • A61M1/165—Constructional aspects thereof with a dialyser bypass on the dialysis fluid line
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403—Regulation parameters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3413—Diafiltration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01L—MEASURING FORCE, STRESS, TORQUE, WORK, MECHANICAL POWER, MECHANICAL EFFICIENCY, OR FLUID PRESSURE
    • G01L13/00—Devices or apparatus for measuring differences of two or more fluid pressure values
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/08—Investigating permeability, pore-volume, or surface area of porous materials
    • G01N15/082—Investigating permeability by forcing a fluid through a sample
    • G01N15/0826—Investigating permeability by forcing a fluid through a sample and measuring fluid flow rate, i.e. permeation rate or pressure change
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/70—General characteristics of the apparatus with testing or calibration facilities
    • A61M2205/705—Testing of filters for leaks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/08—Investigating permeability, pore-volume, or surface area of porous materials
    • G01N2015/084—Testing filters

Definitions

  • the invention relates to an apparatus for testing filters.
  • the invention can be usefully applied for filters of an apparatus for extracorporeal blood treatment, in particular for membrane filters normally used in a device for on-line preparation of a dialysis liquid and/or a replacement liquid, in the ambit of an apparatus for hemodialysis and/or hemo(dia)filtration, with the aim of removing germs contained in the liquid.
  • Membrane filters are used in the production of sterile liquids, by causing the liquid to pass through a semi-permeable membrane able to filter the germs. Also known are various processes for checking the characteristics of the membrane of a filter in order to guarantee its efficiency in treating the germs.
  • BPT bubble point test
  • the test briefly comprises the following stages: the membrane is wetted so that the pores are full of liquid; a first side of the membrane is connected to a gas source, while the opposite side is connected to a liquid for easy detection of gas bubbles; the first side of the membrane is gradually pressurised with the gas; while the gas pressure on the first side remains relatively low, a modest amount of gas will displace, by diffusion, through the liquid contained in the membrane pores towards the second side of the membrane; this amount of gas flow is proportional to the speed of increase of gas pressure on the first side; when the gas pressure reaches a certain level, the liquid contained in the largest pores is forced to exit from the pores themselves, and a considerable amount of gas crosses the largest pores, reaching the liquid connected to the second side of the membrane, forming gas bubbles within the liquid; in this situation a further pressuring action leads to a further displacement of gas towards the second side of the membrane, with no discernible increase in pressure; the substantially stable pressure reached in this situation (bubble point pressure, or BP pressure) is a known function of the maximum radius
  • Prior-art document US 4,614,109 describes a process for checking the permeability of a wet membrane of a filter, based both on a search for the BP pressure and on the determination of the gas diffusion before reaching BP pressure.
  • the filter membrane is first impregnated with liquid; thereafter, the inlet side of the membrane is gradually pressurised by introduction of a gas; the gas that passes by diffusion through the membrane is collected in a graduated container; the permeability of the membrane is calculated on the basis of the transmembrane pressure measured on the two sides o the membrane, and of the quantity of gas diffused through the membrane per unit of time using the graduated container.
  • US 4,614,109 further describes a process by which the transmembrane pressure can be determined by pressure measurements performed only on the inlet side of the membrane, i.e. on the side which, in the case of a sterile filter, is considered non-sterile, with the aim of not contaminating the sterile side of the membrane by performing these measurements. This is done by measuring a pressure gradient between the inlet side of the membrane and a specific reference pressure system which at the outset of each test is connected to the gas source generating the test pressure.
  • US 5,064,529 describes an automatic BPT (without the need to observe the moment of gas bubble formation) to check whether the effective BP pressure of the membrane corresponds to the desired BP pressure corresponding to the maximum diameter of the pores indicated by the membrane manufacturer; in a first stage the first side of the membrane is pressurised with the gas at a predetermined constant pressurisation speed, at the end of which first stage the pressure measured on the first side of the membrane should correspond to a predetermined theoretical pressure; the pressurisation speed and the pressurisation time are chosen so that the above-mentioned theoretical pressure is lower than the desired BP pressure; if the pressure measured after the predetermined time does not correspond to the theoretical pressure, a fault is signalled due, probably, to the breakage of the membrane or a faulty installation of the filter; in a second stage, the pressurisation is halted for a certain time period in which the pressure should remain substantially constant; if, on the contrary, there is a significant drop in pressure, a fault is signalled due, probably, to the faulty filling-up
  • US 5,594,161 describes a process for testing the integrity of one or more filtering elements in which the inlet side of the filter element is wetted and subjected to a gas pressure which is kept constant, while the pressure is measured on the outlet side which, previously, has been made part of a closed system. If, after a predetermined time, the outlet pressure does not exceed a predetermined threshold value, the filter element is considered intact.
  • US 6,228,271 describes a process for testing the integrity of filter membranes in which the filter inlet chamber is emptied of liquid and filled with air at atmospheric pressure, while the outlet chamber remains full of liquid. A depression is then created in the outlet chamber in order to create a transmembrane pressure; after the depression has been stabilised, for example at a value comprised between 0.2 and 0.9 bar (absolute pressure), and before completely evacuating the liquid from the outlet chamber, the constant flow of liquid is measured as it exits the outlet chamber, which corresponds to the air flow passing through the perforations of the membrane; the integrity of the membrane is thus measured on the basis of the value measured for the liquid flow.
  • a typical sealed pressure test involves, for example, a side of the membrane being brought up to a predetermined gas pressure, below BP pressure, comprised in the diffusion range, i.e. a range in which the pressure in the second membrane chamber increases proportionally to the pressure in the first side; when the pressure has been reached, the gas supply is interrupted and the pressure on the first side monitored; if the drop in pressure per time unit exceeds a predetermined threshold value, the membrane is understood to exhibit some defects.
  • US 4,702,829 describes a process, of the pressurised sealed type, for verifying the integrity of the filters of a hemodiafiltration apparatus, in which the substitution liquid is realised on-line by passing the dialyser liquid through two sterile filters arranged one after another, each of which exhibits two chambers separated by a water-wettable and semi-permeable membrane, which can hold the germs.
  • the verification process of the filter seal begins after the dialysis circuit washing stage, with the circuit full of the detergent liquid and the water-wettable filter membranes wet.
  • the filter seal verification process uses an ultrafiltration pump, predisposed in the dialysis circuit downstream of the blood treatment device and used in the dialysis treatment for obtaining a patient weight drop measurement.
  • the ultrafiltration pump is used to aspirate air internally of the first chamber of the second filter, through a microporous water-repelling filter arranged in a breather of the first chamber.
  • the aspirated air can also enter the second chamber of the first filter in the absence of occlusions in the circuit branch comprised between the two filters.
  • the liquid that leaves space for the aspirated air is removed by the ultrafiltration pump through the membranes of the two filters. Given that the water-wettable membranes of the filters are wet, the membranes themselves are substantially impermeable to air.
  • the ultrafiltration pump can generate a depression in chambers occupied by the liquid, i.e. the first chamber of the first filter and the second chamber of the second filter.
  • the ultrafiltration pump is then activated until a determined depression has been reached in a part of the dialysis circuit filled with liquid. Thereafter, the depression is monitored using a pressure gauge, for example by measuring the time necessary for the pressure to rise by a predetermined quantity, or by measuring the depression after a determined period of time. The monitoring of the depression enables an evaluation of the fluid seal of the system constituted by the membranes and the part of the circuit under depression.
  • US 4,834,888 describes a control process of the integrity of a sterile filter arranged in the supply system of a dialyser liquid to a dialyser, according to which the dialyser is removed and the flow in the dialyser liquid circuit interrupted, by stopping the circulation pump or alternatively closing two intercept valves, one arranged on the fresh dialyser liquid supply line and the other on the used dialyser liquid drainage line, closing an intercept valve arranged on a rinse line which unites an exit of the fist chamber of the sterile filter to the drainage line, opening a ventilation valve arranged in the rinse line between the outlet of the first chamber and the intercept valve, start up the ultrafiltration pump which during the dialysis treatment is used for calculating a patient's weight loss, and finally monitoring the pressure using a pressure gauge arranged on the drainage line.
  • the ultrafiltration pump causes the inlet of air through the ventilation valve and thus inside the first chamber of the sterile filter, while the liquid contained in the first chamber is forced to pass through the membrane and thus internally of the second chamber.
  • the wet membrane if intact, represents an air-impermeable barrier, so that the last action of the ultrafiltration pump causes a depression in the part of the circuit which is connected to the second chamber of the sterile filter; when the pressure gauge signals that a predetermined degree of depression has been reached, the ultrafiltration pump is stopped; if, after a predetermined period of time, the depression has not substantially change, the filter membrane is considered to be intact.
  • EP 491981 which concerns a plant for the production of a concentrate for hemodialysis by mixing water with a soluble powder
  • a test is used for verifying the integrity of a filter which is part of the plant.
  • the plant comprises a gas pump which can be used both for eliminating the gas which is freed during the production of the hemodialysis concentrate in a mixing tank, or for generating, in one of the two chambers of the filter, an overpressure which is monitored to evaluate the integrity of the filter membrane.
  • US 5,808,181 describes a process for verifying membrane filters arranged in the dialysis circuit of a device for extracorporeal blood treatment, in which the membrane of a filter to be checked is completely wetted with a liquid, a branch of the dialysis circuit containing one of the two filter chambers to be verified is separated from the rest of the circuit, a gas is injected into the separated branch to cause an overpressure, while the liquid contained in the chamber is removed by passing through the membrane; the gas supply is interrupted after a predetermined overpressure level has been reached in chamber; thereafter, the overpressure is controlled, for example by comparing the pressure drop per time unit with a limit value which is characteristic of an intact filter membrane.
  • This document also discloses an apparatus according to the preamble of claim 1.
  • EP 407737 describes a process for testing the membrane of a dialyser filter in two stages: in a first stage the blood chamber of the dialyser is subjected to a pressure gradient from the blood chamber to the dialyser fluid chamber; in a second stage the membrane is subjected to an opposite gradient. The test enables a determination of the presence of leaks which might appear or be noted only by effect of one or other of the two pressure gradients.
  • the invention is defined by an apparatus according to claim 1. Embodiments of the invention are defined in dependent claims 2 to 5.
  • a principal aim of the present invention is to provide an apparatus for the testing of filters which is reliable and precise without the use of high pressures in the hydraulic circuit connected to the filter or filters.
  • the aim is achieved by generating a transmembrane pressure of the filter to be tested by creating an overpressure on one side of the membrane and a depression on the opposite side thereof.
  • a further aim of the invention is to provide an apparatus which is simple and economical for actuating the above-described process.
  • An advantage of the invention is that it is applicable simply and economically for testing filters of apparatus for extracorporeal blood treatment, such as hemodialysis and hemo(dia)filtration apparatus.
  • a further advantage is that it also makes available a very precise and sensitive verification process for filters which are not suitable (because of breakages, leaks, excessive permeability or pore size, etc.) for relatively minor reasons.
  • This advantage is attained by virtue of a test based on the reading of gas quantities and/or liquid in inlet and/or in outlet to or from the filter chambers.
  • a still further advantage is that the apparatus of the invention provides a process for checking which can be effected relatively rapidly. This is made possible firstly by the fact that the transmembrane pressure is generated using two actuators operating on the two opposite sides of the membrane, and secondly because the evacuation of the liquid from a filter chamber, which is necessary to cause the test gas to enter, is done by a tangential liquid flow which does not cross the membrane.
  • a further advantage is that the invention recognises whether the detection of a faulty situation is due to the unsuitablility of the membrane or whether it is due instead to leakages in other parts of the hydraulic circuit connected to the filter. This advantage is obtained by means of the independent monitoring of both sides of the membrane.
  • the invention advantageously enables detection of which, if one only, of the two filters is at fault, and indeed if only one of them is faulty.
  • 1 denotes in its entirety an apparatus for extracorporeal blood treatment (hemodiafiltration)
  • 2 denotes a fresh dialyser fluid
  • 3 a fresh dialyser fluid circulation pump
  • 4 a first filter having a semipermeable membrane 5 which separates a first chamber 6 from a second chamber 7, 8
  • a blood treatment device having a semipermeable membrane 9 which separates a dialysis chamber 10 from a blood chamber 11, 12 a replacement fluid circulation pump
  • 13 a second filter having a semipermeable membrane 14 which separates a first chamber 15 from a second chamber 16, 17 a used dialyser fluid drainage pump, 18 a used dialyser fluid discharge, 19 a gas pump connected to the atmosphere by a water-repelling air filter 20.
  • the pump 3 is arranged on a first tract of a supply line of the fresh dialysis fluid which connected the source to an inlet 6a of the first chamber 6 of the first filter 4.
  • a second tract of the supply line connects an outlet 7a of the second chamber 7 of the first filter 4 with an inlet 10a of the device 8 dialysis chamber.
  • the pump 17 is arranged on a drainage line for the used dialysis fluid which connects an outlet 10b of the dialysis chamber 10 with the discharge 18.
  • the pump 19 is of a type which occludes the conduit it is operatively associated with when not working.
  • An extracorporeal blood circuit comprises an arterial line LA which takes the patient's blood to an inlet 11a of the blood chamber 11 of the device 8, and a venous line LV which returns the blood from an outlet 11b of the blood chamber 11 to the patient.
  • the infusion pump 12 is arranged on a first tract of an infusion line which branches from the second tract of the dialysis fluid supply line up to an inlet 15a of the first chamber 15 of the second filter 13.
  • the pump 12 is occlusive and reversible and able to move the fluid in both circulation directions.
  • a second tract of the infusion line connects an outlet 16a of the second chamber 16 to the extracorporeal blood circuit (for example with the venous line LV, as shown in figure 1 , and/or the arterial line LA).
  • a first bypass line 21 connects the fresh dialysis fluid supply line, at a point downstream of the pump 3, to the used dialyser liquid drainage line, at a point upstream of the pump 17.
  • a shunt valve V1 selectively directs the fluid coming from the pump 3 either towards the first filter 4 or to the first bypass line 21.
  • a first device for example a flow meter
  • a second device for measuring the fluid flow rate is arranged on the used dialyser fluid drainage line downstream of the bypass line 21.
  • the flow rate measuring devices enable gathering of information relating to the quantity of fluid exchanged between the extracorporeal blood and the dialysis apparatus during treatment, with the aim of controlling the patient's fluid balance, as well-known and used in dialytic treatments.
  • a second bypass line 22 connects the fresh dialyser fluid supply line, at a point downstream of the first bypass line 21, with the used dialyser fluid drainage line, at a point upstream of the first bypass line 21.
  • An intercept valve V2 selectively closes or opens the second bypass line 22.
  • the second bypass line 22 enables a rapid evacuation of liquid from the first chamber 6 of the first filter 4 in the filter checking process, as will be better explained hereinafter.
  • a third bypass line 23 connects an outlet 6b of the first chamber of the first filter 4 with the drainage line at a point upstream of the first bypass line 21.
  • a fourth bypass line 24 connects an outlet 15b of the first chamber 15 of the second filter 13 with the drainage line at a point upstream of the first bypass line 21.
  • the third bypass line 23 and the fourth bypass line 24 have a tract in common.
  • An intercept valve V3 selectively opens or closes the fourth bypass line 24.
  • a gas supply line 25 connects the gas pump 19 with the tract of bypass line in common between the bypass lines 23 and 24.
  • a three-way valve V4 places a first way, connected to the outlets 6b and 15b of the first chambers 6 and 15 of the two filters 4 and 13, in selective communication with a second way connected to the gas pump 19, or with a third way connected to the used dialyser fluid drainage line.
  • a fifth bypass line 26 connects the second tract of the fresh dialyser fluid supply line, at a point downstream of the branch point of the infusion line, with the used dialyser fluid drainage line 21.
  • a shunt valve V5 selectively directs the fluid coming from the branch point either towards the dialysis chamber 10 or to the fifth bypass line 26.
  • An intercept valve V6 selectively closes or opens the fifth bypass line 26.
  • An intercept valve V7 is arranged on the second tract of the fresh dialyser fluid supply line, upstream of the branch point of the infusion line.
  • a connection line 27 connects the second tract of the infusion line with the second tract of the fresh dialysis fluid supply line, at a point comprised between the branching of the first tract of the infusion line and the fifth bypass line 26.
  • An intercept valve V8 selectively opens or closes the second tract of the infusion line.
  • a shunt valve V9 connects a first way, connected to the outlet 16a of the second chamber 16 of the second filter 13, selectively to a second way, connected to the extracorporeal circuit, or to a third way, connected to the connection line 27.
  • a first pressure gauge P1 measures the pressure in a tract of circuit which is connected to the outlet 6b and/or to the outlet 15b of the first chambers of the two filters 4 and 13.
  • a second pressure gauge P2 measures the pressure in a tract of circuit connected to the outlet 7a and/or to the outlet 16a of the second chambers of the two filters 4 and 13.
  • Figure 1 shows, in bold lines, the circuit lines which, during treatment, are normally crossed by the fresh or used dialysis fluid, or by the infusion liquid.
  • a first verification process of the integrity of the first filter 4 and the second filter 13 is now described, starting from a situation in which the apparatus is full of liquid (for example following the apparatus priming stage and before connection to the patient).
  • the pumps 3 and 17 are active; the valve V1 directs the fluid to the first bypass line 21; the gas pump 19 operates directly, taking in air from the outside ambient; the valve V4 opens the way which is connected to the pump 19, closing the way which is connected to the drainage line; the valve V2 is opened so as to enable the air moved by the pump 19 to fill the first chamber 6 of the first filter 4, taking the place of the liquid which, driven by the pump 17, can displace, passing through the second bypass line 22; the second valve V7 is closed so that the second chamber 7 of the first filter 4 remains full of liquid; the infusion pump 12 operates inversely (with respect to the direction it takes during a treatment) while valves V3 and V6 are opened and valve V5 is opened towards the bypass line 26 and is closed towards the device 8, so that the air driven by the pump 19 can fill the first chamber 15 of the second filter 13, taking the place of the liquid removed the pump 12 and the pump 17; the valve V8 is closed and the
  • Figure 2 illustrates, in bold line, the circuit lines crossed by the fluid during the first air-filling stage.
  • valve V2 In a second pressurising stage of the first chambers 6 and 15, (see figure 3 ), the valve V2 is closed and the infusion pump 12 (which can occlude the line) is stopped, so that the communication between the first chambers 6 and 15 and the pump 17 and the discharge 18 is closed, while the valve V3 stays open and valve V4 stays in the position which opens communication of the chambers 6 and 15 with the pump 19; the valves V7 and V8 are opened, and valve V9 opens communication with the connection line 27, in such a way that the second chambers 7 and 16 of the two filters 4 and 13 are connected to the pump 17.
  • the gas pump 19 supplies air to the chambers 6 and 15, generating an overpressure in the chambers, while the action of the drainage pump 17 causes a depression in the chambers 7 and 16, which are full of liquid.
  • a broken line illustrates the part of the hydraulic circuit which is in depression.
  • the pump 3 continues to circulate dialyser liquid, which is deviated by the valve V1 to the bypass line 21 in order then to be sent on to the discharge 18.
  • the second stage terminates when the overpressure and the depression have reached a predetermined test value; basically the pump 19 stops when the pressure P 1 measured by the pressure gauge P1 is P 1 > P max , where P max is a predetermined value; valve V6 closes, isolating chambers 7 and 16 from the pump 17, when the pressure P 2 measured by the pressure gauge P2 is P 2 ⁇ P min , where P min is a predetermined value; in this situation (see figure 4 ) the first chambers 6 and 15 are part of a closed system in overpressure, while the second chambers 7 and 16 are part of a closed system in depression.
  • a third verification stage of the integrity of the membranes 5 and 14 includes monitoring the pressures in the pressure gauges P1 and P2, which can be performed according to various criteria, with the system in the situation illustrated in figure 4 .
  • a first criterion is that after a predetermined period of time ⁇ T, the pressure is measured by pressure gauge P1; if the pressure has dropped by a quantity ⁇ P 1 ⁇ ⁇ P 1max , where ⁇ P 1max is a predetermined threshold value, it is considered that the membranes 5 and 14 are intact; if, on the other hand, after time ⁇ T, the situation is ⁇ P 1 > ⁇ P 1max , it is considered that at least one of the two membranes 5 and 14 is not intact, or that the closed system in overpressure which includes the chambers 6 and 15 has leaks. Alternatively it is possible to check the time the pressure P1 takes to drop beyond a predetermined limit, or to check the speed of drop of pressure P1.
  • both ⁇ P 1 > ⁇ P 1max and ⁇ P 2 > ⁇ P 2max result, it is considered that one of the two membranes 5 and 14 is not intact, while if on the other hand only one of the measured pressure variations ⁇ P 1 and ⁇ P 2 is greater than the respective threshold value, it is considered that the membranes 5 and 14 are intact and that there is a leak in the circuit. It is possible to verify the time the pressure P1 takes to fall below a predetermined limit, and to verify the time pressure P2 takes to rise beyond a predetermined limit, and it can be decided that the membranes 5 and 14 are intact if both times exceed a predetermined minimum time. It is also possible to verify whether the speeds of change of the pressures P1 and P2 both exceed a predetermined threshold speed.
  • the third stage of the verification process can include a first sub-stage, in which verification is made of whether the change in pressure over the time unit exceeds a predetermined threshold, which would mean that one or the other of the membranes 5 and 14 was not intact, and a subsequent second sub-stage in which, if in the first sub-stage an excessive pressure change was detected, i.e.
  • a valve arranged between the two chambers subjected to monitoring (for example valve V3 if the monitored chambers are chambers 6 and 15, or valve V8 if chambers 7 and 16 are monitored, or both) is closed, so that one of the two chambers is isolated from the other and the pressure gauge at work (P1 or P2 or both) is connected only to one chamber; if the excessive change in pressure continues, i.e. if the pressure gauge detects, for a second time, a pressure change which is beyond the threshold value, it is concluded that the non-intact filter is the one connected to the pressure gauge; on the other hand, if the change in pressure stops or slows down, it is concluded that the non-intact filter is the other one.
  • each pressure gauge is connected to a different filter 4 or 13, for example by closing valves V3 and V7, so that pressure gauge P1 is connected to the first filter 4 and pressure gauge P2 is connected to the second filter 13.
  • the verification process comprises a first stage of filling the first chambers 6 and 15 with air, as described herein before with reference to figure 2 , and a second stage of pressurisation of the first chambers 6 and 15, at the end of which, when the overpressure and the depression have reached a respective predetermined test value, the pump 19 is stopped, as in the previous case, when the pressure P 1 measured by the pressure gauge P1 is P 1 > P max , while the valves V7 and V8 stay open, keeping open the communication between the chambers 7 and 16 and the pump 17; in this situation the first chambers 6 and 15 are part of a closed system in overpressure, while the second chambers 7 and 16 are part of a non-closed system kept in depression by the pump 17 which continues to work. It is possible to use the pressure gauge P2 to control the value of the depression and keep it at a predetermined value.
  • the pump 17 is controlled in order to maintain the predetermined depression value inside the chambers 7 and 16.
  • the depression maintained in the chambers 7 and 16 enables an increase to be made in the transmembrane pressure gradient, without increasing the gas overpressure in the chambers 6 and 15, thus without any further strain on the hydraulic circuit.
  • the verification process of the second preferred embodiment is also applicable to a single filter.
  • a first variant can be included, in which during the third monitoring stage the liquid flow is measured as it exits the chambers 7 and 16 of the filters, for example using the difference of the flow rate values measured by the flow meters that the HDF apparatus uses during the treatment for the patient's fluid balance.
  • the liquid flow rate corresponds to the air flow rate passing through the membrane, entering the chambers 7 and 16, which is indicative of the state of the membranes 5 and 14.
  • the depression P 2 in the chambers 7 and 16 is maintained constant at a predetermined value, for example comprised between 0.2 and 0.9 bar (absolute pressure). If the liquid flow rate measured exceeds a predetermined threshold value, it is considered that at least one of the two membranes 5 and 14 is not intact, and exhibits breakage, leakage, or has too-large pores or excessive permeability.
  • a second variant can be included in which, in addition to the first variant, not only the depression P 2 but also the overpressure P 1 in the first chambers 6 and 15 is kept at a constant predetermined value, for example comprised between 1.2 and 3.0 bar (absolute pressure), by activating the pump 19 which supplies the air that passes through the membranes 5 and 14.
  • the air flow supplied by the pump 19 (which can be calculated for example from the pump speed, being a positive displacement pump) corresponds to the flow rate measured for the liquid exiting from the chambers 7 and 16.
  • the air flow rate is also indicative of the state of the membrane.
  • the first chambers 6 and 15 are maintained at a constant overpressure by the pump 19, while the second chambers 7 and 16 are kept at a constant depression by the pump 17; the state of the membrane is evaluated by the air flow rate passing through the membranes 5 and 14 from the first chambers to the second chambers, the flow rate being calculable either by measuring the liquid flow rate exiting the second chambers 7 and 16, or by measuring the air flow rate supplied to the first chambers 6 and 15, or by both of the above-mentioned measurements.
  • the process for verifying the filters 4 and 13 includes filling the chambers 6 and 15 with air, generating a depression in the liquid-filled chambers 7 and 16, forming a closed system which includes the chambers 7 and 16, and monitoring the depression in the chambers 7 and 16.
  • the filters are considered to be intact for example if, after a predetermined time ⁇ T, the pressure measured by the pressure gauge P2 has risen by an amount ⁇ P 2 ⁇ ⁇ P 2max , where ⁇ P 2max is a predetermined threshold value.
  • the testing processes described above can also be applied to a dialysis filter.
  • Figures from 5 to 8 relate to testing processes applied to a single filter of an apparatus for extracorporeal blood treatment.
  • Figure 5 shows an apparatus for dialysis in which the elements that are similar to the apparatus of figure 1 have been indicated for reasons of simplicity using the same enumeration.
  • a first testing process of the filter 4 starting from a situation in which the membrane 5 is wet and the chambers 6 and 7 are both full of liquid, comprises a first emptying stage of liquid from the first chamber 6 and a filling thereof with air coming from the pump 19.
  • the situation is as follows: the pump 17 removes the liquid from the first chamber 6 and sends it towards the discharge 18 with the valve V2 open.
  • the air coming from the outside environment through the hydrophobic filter 20 is supplied by the pump 19 to the first chamber 6 with the valve V4 open towards the pump 19 and closed towards the drainage line, the valve V5 opens toward the bypass 26 and closes towards the port 10a of the dialyser; the valve V6 closes the bypass 26 so that the second chamber 7 does not communicate with the operating pump 17 and remains full of liquid.
  • the first chamber 6 is full of air and the second chamber 7 is still full of liquid.
  • a second stage ( figure 7 ) the first chamber 6 is placed in overpressure and the second chamber 7 in depression: the valve V2 is closed and the pump 19 continues to supply air to the first chamber 6; the valve V6 is open so that the pump 17 communicates with the second chamber 7; the pressure gauges P1 and P2 send the relative pressure signals to a control unit of the apparatus which, as in an example already described herein before, controls the pump 19 so as to maintain a constant overpressure in the first chamber 6 (for example at a value comprised between 1.2 and 3.0 bar in absolute pressure), and the pump 17 so as to maintain a constant depression in the second chamber 7 (for example at a value comprised between 0.2 and 0.9 bar of absolute pressure); the state of the membrane 5 is calculated on the basis of the air flow rate which, in this situation of constant pressures, enters the first chamber 6 and/or the liquid flow rate exiting the second chamber 7.
  • these flow rates can be calculated from the speed of the positive displacement pump 19 and the flow rate data provided by the device the apparatus is provided with for maintaining the fluid balance of the patient during the dialysis treatment.
  • the fluid balancing device can comprise two flow meters (not illustrated) arranged with one on the fresh dialysis fluid supply line and the other on the used fluid drainage line, so that the liquid flow rate exiting the second chamber 7 can be determined by the difference of the flow rates measured by the two flow meters.
  • other fluid balance devices of known type for a dialysis apparatus, can be used in order to calculate the liquid flow rate exiting from the chamber 7.
  • both flow rates exceed a threshold value, it is considered that the membrane 5 is not suitable (for example because it exhibits breakages, leaks, too-large pores and so on). If the two flow rates differ from each other by a predetermined threshold value, it is considered that the membrane is suitable and that there is a leak in the part of the hydraulic circuit on the side where the greater flow rate is measured.
  • a first system (indicated by a long broken lines in figure 8 ) which includes the first chamber 6 and the first pressure gauge P1, is defined between the closed valve V2 and the pump 19 when the latter is still;
  • a second system (indicated with short broken lines in figure 8 ), which includes the second chamber 7 and the second pressure gauge P2, is defined by the closure of the valve V6.
  • a further testing process is also possible, in which a first closed system is formed in air overpressure which includes the first chamber 6, while the second chamber 7 is maintained at a constant depression by the pump 17, keeping the valve V6 open.
  • the monitoring stage includes reading the liquid flow exiting the second chamber 7 (as already described herein-above), as well as the drop in pressure at the pressure gauge P1. In the case that both the liquid flow rate and the pressure drop exceed respective threshold values, the membrane is considered to be unsuitable.
  • a further process consists in maintaining a constant air overpressure in the first chamber 6 by means of the pump 19, while the second chamber 7 is part of a closed system in depression with the valve V6 closed.
  • the monitoring stage includes a monitoring of the increase in pressure at the pressure gauge P2 and reading the air flow entering the first chamber 6 and thus the second chamber 7 due to the compliance of the closed system the chamber 7 is part of. If both the air flow and the pressure increase exceed respective threshold values, the membrane is considered to be unsuitable.
  • the verification processes described above in relation to the dialysis apparatus of figure 5 are also applicable to a hemodiafiltration apparatus comprising, for example, an infusion pump arranged on an infusion line which branches from the dialysis fluid supply line and which incorporates a filter for the infusion fluid, similarly to the apparatus of figure 1 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Fluid Mechanics (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • External Artificial Organs (AREA)
  • Filtering Of Dispersed Particles In Gases (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Networks Using Active Elements (AREA)
EP05762877.8A 2005-07-01 2005-07-01 Apparatus for testing a filter Active EP1898973B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL05762877T PL1898973T5 (pl) 2005-07-01 2005-07-01 Aparat do testowania filtra

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/001887 WO2007003980A1 (en) 2005-07-01 2005-07-01 An apparatus and process for testing filters

Publications (3)

Publication Number Publication Date
EP1898973A1 EP1898973A1 (en) 2008-03-19
EP1898973B1 EP1898973B1 (en) 2010-05-26
EP1898973B2 true EP1898973B2 (en) 2019-08-21

Family

ID=36353310

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05762877.8A Active EP1898973B2 (en) 2005-07-01 2005-07-01 Apparatus for testing a filter

Country Status (10)

Country Link
US (2) US8881600B2 (zh)
EP (1) EP1898973B2 (zh)
JP (1) JP4566262B2 (zh)
KR (1) KR101098125B1 (zh)
CN (1) CN101232910B (zh)
AT (1) ATE468870T1 (zh)
DE (1) DE602005021552D1 (zh)
ES (1) ES2346669T5 (zh)
PL (1) PL1898973T5 (zh)
WO (1) WO2007003980A1 (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230862A1 (en) 2002-04-11 2003-10-27 Deka Products Limited Partnership System and method for delivering a target volume of fluid
ITBO20060625A1 (it) * 2006-09-05 2008-03-06 Bellco Srl Metodo per testare l'integrita' dei filtri di un circuito di dialisi
ES2370985T3 (es) * 2006-12-01 2011-12-26 Gambro Lundia Ab Aparato de tratamiento de sangre.
US8491184B2 (en) 2007-02-27 2013-07-23 Deka Products Limited Partnership Sensor apparatus systems, devices and methods
US8409441B2 (en) 2007-02-27 2013-04-02 Deka Products Limited Partnership Blood treatment systems and methods
CN103845768B (zh) 2007-02-27 2016-09-28 德卡产品有限公司 血液透析系统及方法
US10463774B2 (en) 2007-02-27 2019-11-05 Deka Products Limited Partnership Control systems and methods for blood or fluid handling medical devices
US10201647B2 (en) 2008-01-23 2019-02-12 Deka Products Limited Partnership Medical treatment system and methods using a plurality of fluid lines
WO2009127683A1 (en) * 2008-04-17 2009-10-22 Gambro Lundia Ab Method and devices for monitoring flow circuits
DE102008045422B4 (de) * 2008-09-02 2017-10-12 Fresenius Medical Care Deutschland Gmbh Vorrichtung zum Befüllen eines Filters und Verfahren hierzu
CN101846613B (zh) * 2010-05-25 2011-08-24 浙江大学 不同温度条件下垃圾填埋场排水层淤堵模拟试验装置
EP2418012A1 (en) 2010-08-11 2012-02-15 Gambro Lundia AB Device and process for testing filters
ES2550798T3 (es) * 2010-11-10 2015-11-12 Gambro Lundia Ab Dispositivo para el tratamiento de sangre con extracción selectiva de solutos
JP5986100B2 (ja) * 2010-12-07 2016-09-06 ゾール ライフブリッジ ゲーエムベーハーＺｏｌｌ Ｌｉｆｅｂｒｉｄｇｅ Ｇｍｂｈ フィルタの段階的浸水を伴う体外血液処理用装置の充填および空気抜きを行うための方法
AU2012259459B2 (en) 2011-05-24 2016-06-02 Deka Products Limited Partnership Blood treatment systems and methods
US9999717B2 (en) 2011-05-24 2018-06-19 Deka Products Limited Partnership Systems and methods for detecting vascular access disconnection
ES2565351T3 (es) 2012-09-21 2016-04-04 Gambro Lundia Ab Un aparato de control para tratamiento sanguíneo extracorpóreo
NZ708504A (en) * 2012-12-27 2017-12-22 Medi-Physics Inc Dual-filter dual-integrity test assembly
US10100594B2 (en) * 2013-06-27 2018-10-16 Ge Oil & Gas Uk Limited Control system and a method for monitoring a filter in an underwater hydrocarbon well
GB2515533A (en) * 2013-06-27 2014-12-31 Vetco Gray Controls Ltd Monitoring a hydraulic fluid filter
DE102016000367A1 (de) * 2016-01-15 2017-07-20 Fresenius Medical Care Deutschland Gmbh Vorrichtung zur Durchführung einer extrakorporalen Blutbehandlung und Verfahren zur Zugabe einer Substitutionsflüssigkeit
NZ743477A (en) 2016-01-22 2019-03-29 Baxter Healthcare Sa Method and machine for producing sterile solution product bags
DE102016010434A1 (de) 2016-08-27 2018-03-01 Fresenius Medical Care Deutschland Gmbh Blutbehandlungsvorrichtung und Verfahren zum Betreiben einer Blutbehandlungsvorrichtung
JP6956097B2 (ja) * 2016-09-30 2021-10-27 京セラ株式会社 センサモジュール及び検出方法
DE102017000227A1 (de) * 2017-01-13 2018-07-19 Fresenius Medical Care Deutschland Gmbh Extrakorporale Blutbehandlungsvorrichtung und Verfahren zur Überwachung der Integrität eines Dialysators einer extrakorporalen Blutbehandlungsvorrichtung
US10561778B2 (en) * 2017-03-02 2020-02-18 Fresenius Medical Care Holdings, Inc. Split reservoir bags and method of using split reservoir bags to improve the heating and generation of dialysate
EP3444022A1 (en) 2017-08-16 2019-02-20 Gambro Lundia AB Process for testing filters
WO2019119412A1 (en) * 2017-12-22 2019-06-27 Fresenius Medical Care Deutschland Gmbh Device for measuring filling time of balancing chamber system, device for detecting abnormity in balancing chamber system, balancing chamber module, dialysis system and corresponding method
EP3560577A1 (en) 2018-04-25 2019-10-30 Gambro Lundia AB Apparatus and method for testing integrity of an ultrafilter membrane
WO2019222473A1 (en) * 2018-05-16 2019-11-21 Baxter International Inc. Dialysis transfer set having filter integrity testing
KR102342446B1 (ko) * 2018-10-18 2021-12-22 주식회사 엘지화학 분리막 엘리먼트의 결함 검출 방법 및 분리막 엘리먼트 결함 검출 장치
KR102182592B1 (ko) * 2020-03-10 2020-11-24 이건형 실린더 펌프
US10935474B1 (en) 2020-07-23 2021-03-02 King Abdulaziz University Membrane filter device
EP3968002A1 (en) * 2020-09-09 2022-03-16 Pall Corporation Method and assembly for testing integrity of a filter medium
CN112617072B (zh) * 2020-11-26 2022-06-07 长春豪邦健康科技有限公司 一种基于无菌液体饮品的无菌配制工艺
CN114307662B (zh) * 2021-12-30 2022-11-11 江苏汉邦科技股份有限公司 一种滤芯滤膜完整性测试装置

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3442744A1 (de) † 1984-11-23 1986-06-05 Fresenius AG, 6380 Bad Homburg Dialysegeraet mit einer einrichtung zur wiederverwendung von haemodialysatoren
EP0189561A1 (de) † 1984-12-07 1986-08-06 Fresenius AG Hämodiafiltrationsgerät
EP0270794A2 (de) † 1986-12-08 1988-06-15 Fresenius AG Hämodialysevorrichtung mit Sterilisiereinrichtung
EP0407737A1 (de) † 1989-07-13 1991-01-16 Fresenius AG Verfahren zur Prüfung einer Hämodialysemembran
EP0763367A1 (de) † 1995-09-16 1997-03-19 Fresenius AG Verfahren zum Überprüfen von mindestens einem, in einem Dialysierflüssigkeitssystem
EP1300167A2 (fr) † 1994-07-26 2003-04-09 Hospal Industrie Dispositif et procédé pour déterminer le vieillissement d'un filtre de liquide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2132366B (en) * 1982-12-27 1987-04-08 Brunswick Corp Method and device for testing the permeability of membrane filters
DE3477691D1 (en) * 1983-09-09 1989-05-18 Fujisawa Pharmaceutical Co Apparatus for testing membrane filters, and apparatus for sterilizing liquids with use of membrane filter
DE59008490D1 (de) 1990-12-23 1995-03-23 Fresenius Ag Automatische Anlage zur Herstellung von Konzentraten durch Mischung von Flüssigkeit mit löslichem Feststoff.
DE4209519C3 (de) * 1992-03-24 2000-06-15 Pall Corp Verfahren und Gerät zum schnellen Testen der Unversehrtheit von Filterelementen
DE4239937C2 (de) * 1992-11-27 1995-08-24 Fresenius Ag Verfahren zur Feststellung der Funktionsfähigkeit einer Teileinrichtung eines Hämodialysegerätes und Vorrichtung zur Durchführung dieses Verfahrens
FR2704432B1 (fr) * 1993-04-27 1995-06-23 Hospal Ind Dispositif d'injection de liquide dans un circuit extracorporel de sang.
JPH0852207A (ja) * 1994-08-12 1996-02-27 Toray Medical Kk 血液透析方法および装置
JP3377318B2 (ja) 1995-01-11 2003-02-17 真啓 尾崎 血液浄化装置
FR2749190B1 (fr) * 1996-05-28 1998-09-18 Omnium Traitement Valorisa Procede et installation pour tester in situ l'integrite des membranes de filtration
JP4267197B2 (ja) * 2000-10-26 2009-05-27 日機装株式会社 血液透析装置の除菌フィルタ検査方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3442744A1 (de) † 1984-11-23 1986-06-05 Fresenius AG, 6380 Bad Homburg Dialysegeraet mit einer einrichtung zur wiederverwendung von haemodialysatoren
EP0189561A1 (de) † 1984-12-07 1986-08-06 Fresenius AG Hämodiafiltrationsgerät
EP0270794A2 (de) † 1986-12-08 1988-06-15 Fresenius AG Hämodialysevorrichtung mit Sterilisiereinrichtung
EP0407737A1 (de) † 1989-07-13 1991-01-16 Fresenius AG Verfahren zur Prüfung einer Hämodialysemembran
EP1300167A2 (fr) † 1994-07-26 2003-04-09 Hospal Industrie Dispositif et procédé pour déterminer le vieillissement d'un filtre de liquide
DE69534830T2 (de) † 1994-07-26 2006-10-19 Gambro Industries S.A.S. Vorrichtung und Verfahren zur Bestimmung der Alterung eines Flüssigkeitsfilter
EP0763367A1 (de) † 1995-09-16 1997-03-19 Fresenius AG Verfahren zum Überprüfen von mindestens einem, in einem Dialysierflüssigkeitssystem

Also Published As

Publication number Publication date
JP4566262B2 (ja) 2010-10-20
DE602005021552D1 (de) 2010-07-08
EP1898973A1 (en) 2008-03-19
US20090151470A1 (en) 2009-06-18
US20150033829A1 (en) 2015-02-05
CN101232910A (zh) 2008-07-30
JP2009500058A (ja) 2009-01-08
CN101232910B (zh) 2011-12-14
KR101098125B1 (ko) 2011-12-26
EP1898973B1 (en) 2010-05-26
ATE468870T1 (de) 2010-06-15
WO2007003980A1 (en) 2007-01-11
PL1898973T3 (pl) 2010-10-29
US8881600B2 (en) 2014-11-11
PL1898973T5 (pl) 2020-02-28
US9366615B2 (en) 2016-06-14
ES2346669T5 (es) 2020-03-18
KR20080027357A (ko) 2008-03-26
ES2346669T3 (es) 2010-10-19

Similar Documents

Publication Publication Date Title
EP1898973B2 (en) Apparatus for testing a filter
US6066261A (en) Method of monitoring part of a blood treatment machine and a blood treatment machine with a monitoring device
JP3495068B2 (ja) 血液透析装置の透析器の透析セクションにおける構成部品の操作性を決定するための方法、およびこの方法を実施するための装置
US9243991B2 (en) Device and process for testing hollow fibre membrane filters
CN102458503A (zh) 用于监测体外血液处理设备的流体系统的方法和装置
CN101193670A (zh) 血液透析器含血液侧的无气泡充注生理电解质溶液的方法
US11890402B2 (en) Extracorporeal blood treatment device and method for monitoring the integrity of a dialyzer of an extracorporeal blood treatment device
JPS6150564A (ja) 人工透析装置の血液配管システムを生理的電解質溶液で充填する方法
US20200215493A1 (en) Process for testing filters
CA3009424C (en) Method and apparatus for checking a dialyzer for the presence of a leak
US20220105252A1 (en) Method for filling a membrane
JP3664083B2 (ja) 中空糸膜モジュールのリーク試験方法
KR20200113257A (ko) 환자의 정적 압력을 결정하기 위한 장치 및 방법
US10962455B2 (en) Method for testing the rigidity of a disposable
JP2002126076A (ja) 血液透析装置の除菌フィルタ検査方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PUPPINI, ANNA

Inventor name: SUFFRITTI, MAURO

Inventor name: PEDRAZZI, RENATO

DAX Request for extension of the european patent (deleted)
111Z Information provided on other rights and legal means of execution

Free format text: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR

Effective date: 20081020

17Q First examination report despatched

Effective date: 20090116

111Z Information provided on other rights and legal means of execution

Free format text: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR

Effective date: 20081020

Free format text: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR

Effective date: 20090504

RTI1 Title (correction)

Free format text: APPARATUS FOR TESTING A FILTER

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005021552

Country of ref document: DE

Date of ref document: 20100708

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100526

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2346669

Country of ref document: ES

Kind code of ref document: T3

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100926

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100827

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100927

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Effective date: 20110222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602005021552

Country of ref document: DE

Effective date: 20110222

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100701

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101127

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100701

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100826

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Effective date: 20110222

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Effective date: 20110222

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20190821

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602005021552

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2346669

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20200318

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20220506

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220524

Year of fee payment: 18

Ref country code: PL

Payment date: 20220516

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20220811

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230612

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230607

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230605

Year of fee payment: 19